My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Spectrum Pharmaceuticals (SPPI)
SPPI nasdaq
United States
Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Stock Analysis & Ratings

Spectrum Pharmaceuticals Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Spectrum Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


SPPI Stock Stats

Previous Close$2.02
Bid0 x 0
Ask0 x 0
Today’s Range$1.95 - $2.06
52-Week Range$1.92 - $5.24
Average Volume2.66M
Market Cap$321.58M
P/E Ratio-1.6
Earnings DateNov 11, 2021
Ex-Dividend DateDec 18, 2012

Company Description

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Joseph W. Turgeon
11500 South Eastern Avenue, Henderson, NV, 89052, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Spectrum Pharmaceuticals’s price range in the past 12 months?
Spectrum Pharmaceuticals lowest stock price was $1.92 and its highest was $5.24 in the past 12 months.
    What is Spectrum Pharmaceuticals’s market cap?
    Spectrum Pharmaceuticals’s market cap is $321.58M.
      What is Spectrum Pharmaceuticals’s price target?
      The average price target for Spectrum Pharmaceuticals is $5.75. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $3.00. The average price target represents 193.37% Increase from the current price of $1.96.
        What do analysts say about Spectrum Pharmaceuticals?
        Spectrum Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Spectrum Pharmaceuticals’s upcoming earnings report date?
          Spectrum Pharmaceuticals’s upcoming earnings report date is Nov 11, 2021 which is in 24 days.
            How were Spectrum Pharmaceuticals’s earnings last quarter?
            Spectrum Pharmaceuticals released its earnings results on Aug 12, 2021. The company reported -$0.323 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.025.
              Is Spectrum Pharmaceuticals overvalued?
              According to Wall Street analysts Spectrum Pharmaceuticals’s price is currently Undervalued.
                Does Spectrum Pharmaceuticals pay dividends?
                Spectrum Pharmaceuticals pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 7.65%. Spectrum Pharmaceuticals’s last Notavailable dividend payment was on Dec 28, 2012. Spectrum Pharmaceuticals’s upcoming ex-dividend date is Dec 18, 2012
                  What is Spectrum Pharmaceuticals’s EPS estimate?
                  Spectrum Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Spectrum Pharmaceuticals have?
                  Spectrum Pharmaceuticals has 164,070,000 shares outstanding.
                    What happened to Spectrum Pharmaceuticals’s price movement after its last earnings report?
                    Spectrum Pharmaceuticals reported an EPS of -$0.323 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -3.83%.
                      Which hedge fund is a major shareholder of Spectrum Pharmaceuticals?
                      Among the largest hedge funds holding Spectrum Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Spectrum Pharmaceuticals’s shares valued at 218K.

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis